|
|
|
|
|
| Folgueira,M.A.A.K.; Brentani,H.; Katayama,M.L.H.; Patrão,D.F.C.; Carraro,D.M.; Mourão Netto,M.; Barbosa,E.M.; Caldeira,J.R.F.; Abreu,A.P.S.; Lyra,E.C.; Kaiano,J.H.L.; Mota,L.D.; Campos,A.H.J.F.M.; Maciel,M.S.; Dellamano,M.; Caballero,O.L.S.D.; Brentani,M.M.. |
| Clinical stage (CS) is an established indicator of breast cancer outcome. In the present study, a cDNA microarray platform containing 692 genes was used to identify molecular differences between CSII and CSIII disease. Tumor samples were collected from patients with CSII or CSIII breast cancer, and normal breast tissue was collected from women without invasive cancer. Seventy-eight genes were deregulated in CSIII tumors and 22 in CSII tumors when compared to normal tissue, and 20 of them were differentially expressed in both CSII and CSIII tumors. In addition, 58 genes were specifically altered in CSIII and expression of 6 of them was tested by real time RT-PCR in another cohort of patients with CSII or CSIII breast cancer and in women without cancer.... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Breast cancer; CDNA microarray; Clinical stage; Gene expression. |
| Ano: 2006 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000800013 |
| |
|
|
| Katayama,M.L.H.; Brentani,H.; Abreu,A.P.S.; Barbosa,E.M.; Oliveira,C.T.; Góes,J.C.S.; Brentani,M.M.; Folgueira,M.A.A.K.. |
| In breast cancer patients submitted to neoadjuvant chemotherapy (4 cycles of doxorubicin and cyclophosphamide, AC), expression of groups of three genes (gene trio signatures) could distinguish responsive from non-responsive tumors, as demonstrated by cDNA microarray profiling in a previous study by our group. In the current study, we determined if the expression of the same genes would retain the predictive strength, when analyzed by a more accessible technique (real-time RT-PCR). We evaluated 28 samples already analyzed by cDNA microarray, as a technical validation procedure, and 14 tumors, as an independent biological validation set. All patients received neoadjuvant chemotherapy (4 AC). Among five trio combinations previously identified, defined by nine... |
| Tipo: Info:eu-repo/semantics/other |
Palavras-chave: Breast neoplasms; Discriminant analysis; Doxorubicin; Drug resistance; Neoadjuvant therapy; Reverse transcriptase-polymerase chain reaction. |
| Ano: 2010 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010001200012 |
| |
|
|
|
